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The efficacy of antibiotics to prevent respiratory diseases in swine: A
protocol for a systematic review
Abstract
The treatment and prevention of infectious diseases in pigs is an important aspect of swine production
worldwide. The prudent use of antimicrobials and other therapeutic drugs is a primary responsibility of swine
producers and veterinarians and decisions surrounding the use of drug therapy include considerations such as
cost, efficacy, and food safety. The World Health Organization has published numerous reports urging all
stakeholders concerned with both food-producing animals and humans to establish recommended steps to
enhance the prudent use of antimicrobials (WHO, 2015). Similarly, the Organization for Animal Health has
also published recommendations and position statements regarding prudent use and risk management related
to antimicrobial use in animals (OIE, 2017).
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Author	contributions:	
All	authors	contributed	to	the	development	of	the	review	question	and	the	methodology	
described	in	this	proposal.	JMS	drafted	the	protocol,	with	input	and	final	approval	of	all	co-
authors.	
	
Registration:		
This	protocol	is	archived	in	the	University	of	Guelph’s	institutional	repository	(The	Atrium;	
https://atrium.lib.uoguelph.ca/xmlui/handle/10214/10046)	and	published	online	with	
Systematic	Reviews	for	Animals	and	Food	(SYREAF)	available	at:		http://www.syreaf.org/.	The	
systematic	review	will	be	reported	using	the	Preferred	Reporting	Items	for	Systematic	Reviews	
and	Meta-Analyses	(PRISMA)	statement	guidelines	(Liberati	et	al.,	2009).		This	protocol	is	
reporting	using	the	items	(headings)	recommended	in	the	PRISMA-P	guidelines	(Moher	et	al.,	
2015).	
	
Support.		Funding	support	for	this	systematic	review	/	meta-analysis	/	network	meta-analysis,	
including	the	development	of	the	protocol,	was	provided	by	The	Pew	Charitable	Trusts.	
	
Introduction.	
	
Rationale:		
	
The	treatment	and	prevention	of	infectious	diseases	in	pigs	is	an	important	aspect	of	swine	
production	worldwide.		The	prudent	use	of	antimicrobials	and	other	therapeutic	drugs	is	a	
primary	responsibility	of	swine	producers	and	veterinarians	and	decisions	surrounding	the	use	
of	drug	therapy	include	considerations	such	as	cost,	efficacy,	and	food	safety.	The	World	Health	
Organization	has	published	numerous	reports	urging	all	stakeholders	concerned	with	both	
food-producing	animals	and	humans	to	establish	recommended	steps	to	enhance	the	prudent	
use	of	antimicrobials	(WHO,	2015).		Similarly,	the	Organization	for	Animal	Health	has	also	
published	recommendations	and	position	statements	regarding	prudent	use	and	risk	
management	related	to	antimicrobial	use	in	animals	(OIE,	2017).			
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Respiratory	diseases	are	an	important	cause	of	morbidity	and	mortality	in	intensively	–reared	
pigs,	leading	to	reduced	swine	welfare	and	economic	losses	due	to	reduced	growth	efficiency	
and	the	cost	of	treating	illness	(Sorenson	et	al.,	2006).		A	variety	of	infectious	disease	agents	are	
involved	in	respiratory	disease	in	swine,	including	Mycoplasma	hyopneumoniae,	Pasteurella	
multocida,	Actinobacillus	pleuropneumoniae,	swine	influenza	viruses,	and	porcine	reproductive	
and	respiratory	syndrome	virus	(PRRSV)	(Choi	et	al.,	2003,	Sorensen	et	al.,	2006).		Antibiotic	
therapy	is	used	both	to	treat	and	to	prevent	respiratory	diseases	in	pigs	and	there	are	
numerous	pathogenic	organisms	involved	in	all	of	the	predominant	swine	respiratory	diseases	
(Karriker,	et	al,	2012).		However,	while	there	are	many	studies	that	have	assessed	the	efficacy	
of	antibiotics	for	the	prevention	of	pneumonia	associated	with	one	or	more	disease	agent,	they	
often	report	conflicting	results,	making	decisions	around	treatment	and	prevention	complex	
(Thacker	and	Minion,	2012).			
	
Understanding	the	efficacy	of	antibiotics	used	to	prevent	respiratory	diseases	in	swine	is	
essential	to	optimizing	their	use;	ineffective	antibiotics	should	not	be	used	for	prevention	or,	if	
there	are	multiple	efficacious	antibiotics,	then	their	importance	to	human	medicine	should	be	
considered	when	making	decisions	on	antibiotic	use.	Systematic	reviews	of	randomized	
controlled	trials,	and	network	meta-analysis	to	provide	input	on	relative	antibiotic	efficacy,	will	
yield	the	highest	level	of	evidence	for	efficacy	of	treatments	under	field	conditions	(Sargeant	
and	O’Connor,	2014).			
	
Objectives:		The	objective	of	this	protocol	is	to	describe	the	methods	for	a	systematic	review	–	
network	meta-analyses	to	address	the	question:	“What	is	the	efficacy	of	antibiotics	to	prevent	
respiratory	disease	in	swine?”		 
			The	specific	PICO	elements,	which	will	define	the	eligibility	criteria,	are	as	follows:	
i. Population:	Live	swine	at	any	stage	of	production.		
ii. Intervention:	Antibiotics	licensed	for	use	in	swine	administered	parenterally,	in	the	feed,	
or	in	the	water	at	labelled	therapeutic	dose.		Eligible	antibiotics	include	any	antibiotic	
licensed	for	use	for	respiratory	disease	in	swine	included	in	the	OIE	list	of	antimicrobial	
agents	of	veterinary	importance1	(see	also	appendix	1).	
iii. Comparator:		Placebo,	untreated	control	group,	or	an	alternative	antibiotic	treatment.			
iv. Outcomes:		The	outcomes	of	interest	are	respiratory-related	morbidity	(as	defined	by	the	
authors),	mortality,	and	total	antibiotic	use	over	any	period	of	time	within	the	same	
production	stage.	
	
Methods	
	
Eligibility	criteria:		In	addition	to	eligibility	criteria	inherent	in	the	PICO	elements	described	
above,	eligibility	includes	publication	in	English.		Both	journal	articles	and	other	forms	of	
research	reports	are	eligible,	provided	they	report	the	results	of	a	primary	research	study	with	a	
                                                
1 OIE	list	of	antimicrobial	agents	of	veterinary	importance	(May	2015)	available	at:	
http://www.oie.int/fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/Eng_OIE_List_antimicrobials_May201
5.pdf 
 3 
concurrent	comparison	group	using	an	eligible	study	design	and	with	a	full	text	of	more	than	
500	words.			
	
Study	designs	eligible:		Controlled	trials	with	natural	disease	exposure	(individual	or	cluster	
allocated)	will	be	eligible	for	inclusion,	although	we	will	document	the	number	of	controlled	
trials	with	deliberate	disease	challenge	and	analytical	observational	studies	at	full	text	
screening	and	also	will	identify	the	antibiotics	used	and	whether	any	of	the	outcomes	of	
interest	were	assessed	for	studies	of	these	designs.		
	
Information	sources:			
	
We	will	conduct	the	literature	search	in	a	range	of	relevant	bibliographic	databases	and	other	
information	sources	containing	both	published	and	unpublished	literature.	Table	1	presents	the	
resources	to	be	searched.		
	
Table	1:		Databases	and	information	sources	to	be	searched	
	
Database	/	information	source	 Interface	/	URL	
MEDLINE	 PubMed	
CAB	Abstracts		 CAB	Interface	
Science	Citation	Index		 Web	of	Science	
Conference	 Proceedings	 Citation	 Index	 –	
Science	
Web	of	Science	
Agricola	 Proquest	
	
The	AASV	maintains	a	searchable	digital	library	of	proceedings	from	the	prominent	swine	
conferences	through	the	American	Association	of	Swine	Veterinarians	website	(Swine	
Information	Library	http://www.aasv.org/library/swineinfo/).	Selected	proceedings,	as	noted	
below,	will	be	hand-searched	for	potentially	relevant	articles.	
	
Resources	to	be	searched	on	this	site	include	proceedings	from:		
o	AASV	Annual	Meeting	(1999-2018)		
o	International	Pig	Veterinary	Society	Congress	(2000,	2002,	2004,	2006,	2008,	2010,	2012,	
2014,	2016,	2018)	
	
A	 single	 reviewer	 will	 also	 search	 the	 USDA	 FDA	 FOI	 requests	 for	 antibiotics	 registered	 for	
prophylactic	use	for	respiratory	diseases	of	swine	in	the	USA.		A	single	reviewer	will	also	check	
the	reference	lists	of	all	included	studies	for	any	eligible	studies	that	may	have	been	missed	by	
the	database	searches.	
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Search	strategy:			
	
A	Science	Citation	Index	(Web	of	Science)	search	strategy	designed	to	identify	studies	of	
antibiotic	use	to	prevent	for	respiratory	disease	in	swine	is	presented	in	Table	2.	The	search	
strategy	employs	a	multi-stranded	approach	to	maximize	sensitivity.		The	conceptual	structure	
is	as	follows:	
	
•	 Swine	at	any	stage	of	production;		
AND	
•	 Antibiotics;	
AND	
• Respiratory	outcomes	
AND	
• Disease	prevention	(as	opposed	to	treatment)	
	
	
Table	 2:	 Search	 strategy	 to	 identify	 studies	 of	 antibiotics	 for	 the	 prevention	 of	 respiratory	
diseases	in	swine	using	Science	Citation	Index	(Web	of	Science)	
	
#1				TS=	(swine	OR	pig*	OR	piglet*	OR	gilt*	OR	boar*	OR	sow*	OR	hog*	OR	wean*	OR	porcine	
NOT	guinea)		 			910,721	 	
	
#2				TS	=	(medicat*	OR	antimicrobial*	OR	"anti-microbial*"	OR	antibiotic*	OR	"anti-biotic*"	OR	
antibacterial*	OR	"anti-bacterial*"	OR	antiinfect*	OR	"anti-infect*"	OR	bacteriocid*	OR	
bactericid*	OR	microbicid*	OR	"anti-mycobacteri*"	OR	antimycobacteri*)								794,310	
	
#3				TS	=	(amoxicillin	OR	amoxycillin	OR	ceftiofur	OR	danofloxacin	OR	enrofloxacin	OR	
florfenicol	OR	gentamycin	OR	gentamicin	OR	lincomycin	OR	oxytetracycline	OR	penicillin	OR	
spectinomycin	OR	streptomycin	OR	tilmicosin	OR	trimethoprim	OR	tulathromycin	OR	tylosin	OR	
tildipirosin	OR	Neomycin	OR	Cefquinome	OR	Tylvalosin	OR	Phenoxymethylpenicillin	OR	
Tiamulin	OR	Marbofloxacin	OR	Sulfadiazine	OR	Sulfamethazine	OR	Sulfadoxine	OR	
Sulfamerazine	OR	Sulfapyridine	OR	sulfathiazole	OR	Tetracycline	OR	gamithromycin)				159,466	
	
#4					TS	=	(ceffect	OR	ceftiocyl	OR	Baytril	OR	Kinetomax	OR	Marbox	OR	Forcyl	OR	Excede	OR	
Excenel	OR	Naxcel	OR	Cevaxel	OR	Draxxin	OR	Zactran	OR	Zuprevo	OR	Lincomix	OR	Liquamycin	
OR	Agrimycin	OR	Engemycin	OR	Nuflor	OR	Florkem	OR	“Agri-cillin”	OR	Depocillin	OR	Tylan	OR	
Vetramoxin	OR	marobocyl	OR	“neo-chlor”	OR	“neo-tetramed”	OR	medprodex	OR	alamycin	OR	
cyclosol	OR	“bio-mycin”	OR	oxymycine	OR	noromycin	OR	oxyvet	OR	oxy	OR	potencil	OR	parasail	
OR	duphatrim	OR	Trimediazine	OR	tribrissen	OR	trimidox	OR	norovet	OR	borgal	OR	“dofatrim-
ject”	OR	sulvit	OR	sulmed	OR	sulfavite	OR	sulfa	OR	onycin	OR	tetramed	OR	tiamulin	OR	
denagard	OR	pulmotil	OR	tilmovet	OR	aivlosin	OR	sulfamed	OR	tetra)							61,748		
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#5		TS	=	(pneumonia	OR	pleuritis	OR	pleuropneumonia	OR	pleuropneumoniae	OR	respiratory	
OR	SRD	OR	PRDC	)								495,043	 		 	
	
#6		TS	=	(prophyla*	OR	metaphyla*	OR	"meta-phyla*"	OR	“mass	treatment”	or	“mass	
medication”	or	“blanket	medication”	or	“blanket	treatment”	OR	prevent*	OR	“in	feed”	OR	“in-
feed”	OR	“in-water”	OR	“in	water”	OR	medicate)				1,822,316	 
 
	
#1	AND	(#2	OR	#3	OR	#4)	AND	#5	AND	#6										413	
	
The	search	strategies	will	not	be	limited	by	date,	language,	or	publication	type.			
	
We	will	 conduct	 searches	using	each	database	 listed	 in	 the	protocol,	 translating	 the	 strategy	
appropriately	to	reflect	the	differences	in	database	interfaces	and	functionality.			
	
Study	records:	
	
			 Data	management:		We	will	download	the	results	of	searches	in	a	tagged	format,	load	them	
into	bibliographic	software	(EndNote)	and	de-duplicate	the	citations.		We	will	save	results	from	
resources	that	do	not	allow	export	in	a	format	compatible	with	EndNote	in	Word	or	Excel	
documents	as	appropriate	and	manually	de-duplicate.		The	de-duplicated	search	results	will	be	
uploaded	into	online	systematic	review	software	(DistillerSR®,	Ottawa,	ON,	Canada).	Reviewers	
will	have	training	in	epidemiology	and	in	systematic	review	methods.		Prior	to	both	abstract	and	
full-text	screenings,	data	extraction,	and	risk	of	bias	assessment,	the	reviewers	assigned	to	each	
step	will	undergo	training	to	ensure	consistent	data	collection	using	the	forms	created	in	
DistillerSR®.		
	
				Selection	process:			In	the	first	round	of	screening,	abstracts	and	titles	will	be	screened	for	
eligibility.	Two	reviewers	will	independently	evaluate	each	citation	for	relevance	using	the	
following	questions:	
1)	Is	this	a	primary	study	evaluating	the	use	of	one	or	more	antibiotics	to	prevent	respiratory	
disease	in	swine?		
YES	(neutral	response),	NO	(EXCLUDE),	UNCLEAR	(neutral	response)	
2) Is	there	a	concurrent	comparison	group?	(i.e.	controlled	trial	with	natural	or	deliberate	
disease	exposure	or	analytical	observational	study)?	
YES	(neutral	response),	NO	(EXCLUDE),	UNCLEAR	(neutral	response)	
3) Is	the	full	text	available	in	English?		[language	of	publication	can	be	included	as	a	field	in	
DistillerSR]	
YES	(include	for	full	text	screening),	NO	(EXCLUDE),	UNCLEAR	(include	for	full	text	
screening)	
	
Citations	will	be	excluded	if	both	reviewers	responded	“no”	to	any	of	the	questions.		Any	
disagreements	will	be	resolved	by	consensus.		If	consensus	cannot	be	reached,	the	article	will	
be	marked	as	“unclear”	and	will	advance	to	full	text	screening.		A	pre-test	will	be	conducted	by	
 6 
all	reviewers	on	the	first	250	abstracts	to	ensure	clarify	of	questions	and	consistency	of	
understanding	of	the	questions.	
Following	title/abstract	screening,	eligibility	will	be	assessed	through	full-text	screening,	using	
the	questions	included	below.	Two	reviewers	will	independently	evaluate	the	full	text	articles,	
with	any	disagreements	resolved	by	consensus.	If	consensus	cannot	be	reached,	a	third	
reviewer	will	be	used.	A	pre-test	will	be	conducted	by	all	reviewers	on	the	first	10	full	texts	to	
ensure	clarify	of	questions	and	consistency	of	understanding	of	the	questions.	
1) Is	the	full	text	available	with	>	500	words?		
YES	(neutral	response),	NO	(EXCLUDE)	
2) Is	the	full	text	available	in	English?		
YES	(neutral	response),	NO	(EXCLUDE)	
3) Eligible	population:	Does	the	study	evaluate	live	swine?		
YES	(neutral	response),	NO	(EXCLUDE)	
4) Eligible	intervention:	Does	the	study	assess	the	use	of	one	or	more	of	the	antibiotics	of	
interest*	for	the	PREVENTION	of	respiratory	disease(s)?		
*	One	or	more	of	the	antibiotics	licensed	for	respiratory	disease	at	the	labelled	dose	
								YES,	at	the	approved	dose	(neutral	response),	YES,	but	at	a	different	dose	(EXCLUDE),	
NO	(EXCLUDE)	
5) Are	at	least	one	of	the	following	outcomes	described:	respiratory	disease	related	
morbidity,	mortality,	antibiotic	use.	
YES	(neutral	response),	NO	(EXCLUDE)	
6) Is	there	a	concurrent	comparison	group?	(i.e.	controlled	trial	with	natural	or	deliberate	
disease	exposure	or	analytical	observational	study)?	
YES	(neutral	response),	NO	(EXCLUDE)	
7) Eligible	study	design:	Is	the	study	a	controlled	trial	with	natural	disease	exposure?	
Yes	(moves	to	data	extraction	stage),	
No,	the	study	is	a	controlled	trial	with	deliberate	disease	induction	(indicate	the	
antibiotic(s)	evaluated,	but	exclude	from	data	extraction)	
No,	the	study	is	an	observational	study	(indicate	the	antibiotic(s)	evaluated	but	
exclude,	from	data	extraction)	
	
	
			Data	collection	process:		Data	will	be	extracted	by	two	reviewers	working	independently.		Any	
disagreements	will	be	resolved	by	consensus	or,	if	consensus	cannot	be	reached,	a	third	
reviewer	will	be	used.		Authors	will	not	be	contacted	to	request	missing	data	or	to	clarify	
published	results.		A	form	for	data	extraction	will	be	created	for	this	review	in	DistillerSR®	and	
pre-tested	on	4	full	text	articles	to	ensure	question	clarity.	
	
Data	items:		
	
Study	level	data	to	be	extracted	include:	
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• Country	 where	 trial	 was	 conducted	 (if	 not	 stated,	 use	 country	 affiliation	 of	
corresponding	author)	
• Commercial	versus	research	trials	
• Number	of	herds	enrolled	in	study	
• Year(s)	the	study	was	conducted	
• Months	of	data	collection	
• Stage(s)	of	production		
	
Arm	level	data	collected:	
• Antibiotic	name(s)	
• Dose	/	route	/	frequency	of	administration	
• Unit	of	allocation	(individual,	pen)	
• Description	of	comparison	group		
• Number	of	animals	enrolled	
• Number	of	pens	enrolled	
• Number	of	animals	/	pens	lost	to	follow	up	
• Number	of	animals	/	pens	analyzed	
• Any	additional	concurrent	treatments	given	to	both	intervention	groups.	
• The	 approach	 used	 in	 the	 analysis	 to	 account	 for	 non-independent	 observations	 (not	
applicable,	not	reported,	random	effects,	GEE,	other)	
	
	
Outcomes	and	prioritization:			
	
• Respiratory-related	morbidity,	
• Mortality,	
• Total	antibiotic	use,	
	
These	outcomes	were	prioritized	based	on	their	impact	on	animal	health	and	welfare	and	their	
economic	importance.		Formal	evaluation	of	these	criteria	for	prioritization	was	not	
undertaken.	
	
The	specific	outcome	data,	as	described	below,	will	be	extracted	only	for	experimental	studies	
with	natural	disease	exposure.	
	
Outcome	data	to	be	collected:	
1) Respiratory-related	morbidity	
a. Case	definition	
b. Time	period	for	assessing	outcome,	frequency	of	outcome	assessment	
c. Level	at	which	outcome	data	were	measured	(animal	/	pen	/	herd)	
	
2) Mortality	
a. Level	at	which	outcome	data	were	measured	(animal	/	pen	/	herd)	
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b. Time	period	for	assessing	outcome	
	
3) Total	antibiotic	use	
a. Measure	used	to	define	outcome	
b. Time	period	for	assessing	outcome	
c. Antibiotic(s)	used	
	
For	each	outcome,	we	will	extract	the	possible	metrics	in	the	following	order:		
• 1st	priority:	Adjusted	summary	effect	size	(adjusted	risk	ratio	or	adjusted	odds	ratio,	mean	
differences	for	continuous	outcomes)	and	variables	included	in	adjustment	and	
corresponding	precision	estimate		
• 2nd	priority:	Unadjusted	summary	effect	size				
• 3rd	priority:	Arm	level	risk	of	the	outcome,	or	arm	level	mean	of	the	outcome	
(continuous	outcomes)	
• Variance	components.	
	
Risk	of	bias	in	individual	studies:		Risk	of	bias	will	only	be	assessed	for	controlled	trials	with	
natural	disease	exposure.		Risk	of	bias	assessment	will	be	performed	at	the	outcome	level	for	
each	outcome	using	the	Cochrane	risk	of	bias	instrument	(Higgins	et	all,	2016),	with	the	
signaling	questions	modified	as	necessary	for	the	specific	review	question.	The	ROB-2.0	for	
clustered	RCTs	and	individual	RCTs	will	be	used	depending	on	the	study	design	(Higgins	et	al.,	
2016).	These	tools	are	available	at	https://sites.google.com/site/riskofbiastool/welcome/rob-2-
0-tool.	
	
Data	synthesis:		
	
Network	meta-analysis.	Network	meta-analysis	(aka	mixed	treatment	comparison	meta-
analysis)	will	be	conducted	for	each	outcome.		Network	meta-analysis	will	use	the	approach	
described	by	NICE	Decision	Support	Unit	technical	document	(Dias	et	al.,	2014;	O’Connor	et	al.,	
2013;	O’Connor	et	al.,	2016).	The	approach	to	reporting	will	use	the	PRISMA-	NMA	
(http://www.prisma-statement.org/Extensions/NetworkMetaAnalysis.aspx).		Planned	a	priori	
sub-group	analyses	will	be	conducted	for	randomized	versus	non-randomized	trials.		
	
Meta-bias(es):		Small	study	effects	(“publication	bias”)	will	be	assessed	for	all	antibiotic-
comparator	combinations	where	there	are	at	least	10	studies	in	the	meta-analysis.	If	feasible,	
we	will	use	approaches	to	assessing	publication	bias	in	the	network	of	evidence	using	
previously	proposed	approaches	(Mavridis	et	al.,	2013;	Mavridis	et	al.,	2014).		
	
Confidence	in	cumulative	evidence:		The	quality	of	evidence	for	each	outcome	will	be	assessed	
using	 the	 approach	 proposed	 by	 GRADE	 (GRADE,	 2015,	 Puhan	 et	 al.,	 2014),	 while	 also	
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considering	the	nature	of	the	network	meta-analysis	 (Jansen	et	al.,	2011).	 	 If	 feasible,	we	will	
use	the	framework	from	the	CINeMA	platform	for	conveying	the	impact	of	risk	of	bias	on	the	
network	performance.				
Discussion:		
	
This	systematic	review	will	provide	a	synthesis	of	the	current	evidence	regarding	the	efficacy	of	
antibiotics	used	to	prevent	respiratory	diseases	in	swine.		Results	will	be	helpful	for	
veterinarians	and	swine	producers	when	making	evidence-informed	decisions	regarding	
treatment	options	to	reduce	respiratory	illness	and	death,	and	potentially	reduce	the	need	to	
use	antibiotics	to	treat	respiratory	diseases.		The	results	also	will	be	helpful	for	identifying	
specific	gaps	in	knowledge	related	to	the	efficacy	of	prophylactic	antibiotics	for	respiratory	
disease	to	target	additional	research.	
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Appendix	1:		Antibiotics	approved	for	use	in	swine	from	OIE	list,	with	trade	names	and	
labelling		
	
 
Antibiotic	 Trade	name	 Dose	
Amoxicillin	 Vetramoxin	LA	 15	mg/kg	twice,	48h	apart	
Amoxicillin	(	trihydrate)	 amoxicillin	SP	
20	mg	(16	mg	amoxicillin	
trihydrate)/kg	b.w.	daily,	
equivalent	to	1	g	Amoxicillin	
SP/50	kg	b.w./day,	for	3-5	
consecutive	days.	
Cefquinome	
Ceffect	25	mg/ml	Suspension	for	
Injection	for	Cattle	and	Pigs	(BAYER)	
For	respiratory	disease	
administer	2	mg	
cefquinome/kg	bodyweight	(2	
ml/25	kg	bodyweight)	once	
daily	for	3	consecutive	days.	
Ceftiofur	(cystalline	free	acid)	
Excede®	100	Sterile	Suspension	(Pr)	
(Zoetis)	
Give	single	dose	in	post-
auricular	region	of	neck	of	5	mg	
ceftiofur	equivalents/kg	(1	
mL/20	kg)	b.w.		
Ceftiofur	(hydrochloride)	
Ceftiocyl	
(Pr)(Vetoquinol),	
Cevaxel®	RTU	
Sterile	
Suspension	(Pr)	
(Ceva	Animal	
Health).	
Excenel/Excenel	
RTU	EZ	
3	mg/kg	b.w.	(1	mL/17	kg	b.w.).	
Repeat	q24h	for	3	treatments.	
Do	not	inject	more	than	10	
mL/site	//	3-5	mg/kg	SID	q3	
days	
Ceftiofur	(sodium)	
Ceftiofur	Sodium	for	Injection	(Pr)	
(Bio	Agri	Mix),	Excenel®	Sterile	
Powder	(Pr)	(Zoetis),	Naxcel/Cevaxel	
1	mL/17	kg	(3	mg/kg)	b.w.	
Repeat	q24h	for	3	treatments.	
Danofloxacin	
	
1.25	mg/kg	SID	3	days	
Enrofloxacin	
Baytril	100	(Bayer),	Kinetomax,	
Baytril	Max,	Baytril	OneJect	
Administer	once,	behind	the	
ear,	a	S.C.	dose	of	7.5	mg/kg	
(0.75	mL/10	kg)	b.w.		
Florfenicol		
Florkem®	(Pr)	(Ceva	Animal	Health),	
Nuflor®	(Pr)	(Merck	Animal	Health),	
Nuflor	Swine	injectible	
15	mg/kg	(2.25	mL/45	kg)	b.w.	
in	the	neck	only.	Repeat	in	48h.		
Gamithromycin	 Zactran	 6	mg/kg	once	
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Gentamycin	(sulfate)	
Gentamycin	50	/	Gentamycin	100/	
Genta-100	 2	mg/kg	to	5	mg/kg	BID	q	3days	
lincomycin	(hydrochloride)	
Lincomycin	110	Premix	(Bio	Agri	
Mix)	
Growing	swine:	2	kg/tonne	of	
complete	feed	(220	g	
lincomycin	base/tonne).	Feed	
as	sole	ration	for	21d.	
	
lincomix	100/300	mg/ml)	 5	mg/lb	(2.27	mg/kg)	once	
	
Lincomycin	44	Premix	(Bio	Agri	Mix)	 "	"	
	
Lincomycin	44	G	Premix	(Bio	Agri	
Mix)	
Growing	swine:	5	kg/tonne	of	
complete	feed	(220	g	
lincomycin	base/tonne).	Feed	
as	sole	ration	for	21d.	
	
Lincomix®	44	Premix	(Zoetis)	 "	"	
Marbofloxacin	
Marbox/Marobocyl	
(100mg/ml)/Forcyl	Swine	
(160mg/ml)	
2	mg/kg	SID	q	3	days	/	8mg/kg	
once	
Neomycin	sulfate,	tetracycline	 Neo-Chlor®	(Pr)	(Vetoquinol)	
Swine	and	newborn	piglets:	
100	g,	10	kg	sizes:	Dissolve	4	g	
powder/170	mL	water/45	kg	
b.w.	as	a	drench	or	dissolve	200	
g	(2	pouches)	powder/225	L	
water	for	4-5d.	400	g	size:	
Dissolve	4	g	powder	in	170	mL	
water/45	kg	b.w.	as	a	drench	or	
dissolve	800	g	(2	pouches)/900	
L	water	for	4-5d.	
	
Neo-Tetramed	(Medprodex)	
Swine:	2	g/170	mL	of	water	per	
45	kg	b.w.	as	a	drench	OR	100	
g/225	L	drinking	water	for	4-5	
d.		
Newborn	piglets:	4	g/60	mL	
water	and	give	5	mL/piglet	
q12h	for	4-5d.	
Oxytetracycline	
Alamycin	LA	(Pr)	(Vetoquinol),	
Cyclosol	200	LA	(Dominion),	
Liquamycin	LA-200®	(Zoetis),	Bio-
Mycin®	200	(Pr)	(Boehringer),	
Oxymycine	LA	(Zoetis),	Noromycin	
LA	(Kane	Veterinary	Supplies)	
1	mL/10	kg	(20	mg	/kg)	b.w	as	a	
single	dose.	Maximum	5	
mL/injection	site.	1	mL/10	kg	
(20	mg/kg)	b.w.	Maximum	5	
mL/injection	site.		
Pigs	<10	kg	b.w.:	Give	1	
mL/animal.	
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liquamycin	LA-200	
(200mg/ml)/Agrimycin	
200/Engemycin	(100	mg/ml)	
9	mg/lb	(4.1	mg/kg)	once	/	5	
mg/kg	to	10	mg/kg	once	
	
Oxytetracycline	HCI	Soluble	Powder	
1000	(Bio	Agri	Mix)	
Individual	treatment:	5	g/1,000	
kg	b.w.	dissolved	in	water,	
q12h	for	2-3d.		
Mass	medication:	10	g/900	kg	
b.w.	in	drinking	water	
consumed	daily.		
Individual	treatment:	5	g/1,000	
kg	b.w.	dissolved	in	water,	
q12h	for	2-3d.		
Mass	medication:	10	g/900	kg	
b.w.	in	drinking	water	
consumed	daily.		
	
Oxyvet®	200	LA	(Pr)	(Vetoquinol)	 `	
	
Oxy	250	(Medprodex)	
1	g/25	kg	b.w.	q12h	as	a	drench	
OR	2	g/4	L	of	water	OR	100	
g/200	L	drinking	water	for	4-5d.	
	
Oxy	1000	(Jaapharm)	
1	tsp/1,000	kg	(2,200	lb.)	b.w.	
for	3-4d.	
	
Oxyvet®	100	LP	(Pr)	(Vetoquinol),	
Oxymycine	LP	(Zoetis)	 3	mL/45	kg	b.w.	q24h	for	2-3d.		
Penicillin		 Agri-cillin	/	Depocillin	300	mg/ml	
3000	units	per	lb	SD	q	4	days	/	
15	I.U./kg	SID	q	4	days	
Penicillin	(G	procaine)	
Depocillin®	(Pr)	(Merck	Animal	
Health)	
1	mL/20	kg	b.w.	(15,000	IU/kg	
b.w.)	q24h	until	2d	after	clinical	
signs	disappear.		
Phenoxymethylpenicillin	
(potassium)	
Potencil	10%	Premix	for	PigsBy	
CompanyPotencil	10%	Premix	for	
Pigss	(Elanco	Animal	Health)	
For	oral	administration	after	
incorporation	in	pelleted	feed	
or	meal	at	an	inclusion	level	of	
2	kg	Potencil	per	tonne	of	feed.	
This	is	approximately	
equivalent	to	10	mg	
phenoxymethyl	penicillin	
potassium	per	kg	bodyweight	
daily.		
Streptomycin	(amphotericin	B)	 ParaSail™	(Merial)	
Healthy	swine	>=3	weeks	of	
age:	1	mL	reconstituted	
vaccine.	
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Sulfadiazine	 Duphatrim	IS	Injectible	(Zoetis)	
	15mg	of	active	ingredients	per	
kilogram	bodyweight	(1ml	per	
16kg	bodyweight)	once	by	
intramuscular	or	slow	
intravenous	injection.	
	
Trimediazine	15%	Premix	for	
Medicating	feeding	stuff	
(vetoquinol)	
Feed	intake	per	day	per	
kg	bodyweight	
Inclusion	rate	per	tonne	of	feed	
Up	to	35	g	---	2.75–5.5	kg 
35–40	g	---	2.50–5.0	kg 
40–45	g	----2.25–4.5	kg 
45–50	g---2.00–4.0	kg 
50–55	g---1.75–3.5	kg 
55–65	g---1.50–3.0	kg	
	
Tribrissen	48	%	suspension	for	
injection	
1	ml	per	32	kg	(70	lb)	body	
weight	daily,	i.e.	equivalent	to	
15	mg	active	ingredients/kg	
body	weight.	In	cases	of	severe	
infection	the	dose	may	be	
increased	to	1.5	ml	per	32	kg	
(70	lb)	daily	i.e.	equivalent	to	
22.5	mg	active	ingredients/kg	
body	weight.	
Sulfadoxine	(trimethoprim)	
Trimidox	(Pr)	(Vetoquinol),	Norovet	
TMPS	(Pr)	(Kane	Veterinary	
Supplies),	Borgal®	(Pr)	(Merck	
Animal	Health),	Dofatrim-ject	(Pr)	
(Rafter	8)	
1	mL/15	kg	(16	mg/kg)	b.w.	
q24h.		
Piglets	<4.5	kg	(10	lb):	0.5	mL	
maximum.		
Sulfamerazine	(in	combo	with:	
calcium	chloride,	calcium	
pantothenate,	magnesium	
sulfate,	niacinamide,	potassium	
chloride,	riboflavin	(vitamin	B2),	
sodium	acetate,	sodium	
chloride,	sulfamerazine,	
sulfamethazine,	sulfathiazole,	
vitamin	A,	vitamin	B12,	vitamin	
D3)	 3-Sulvit	(Pr)	(Vetoquinol)	
Dissolve	450	g	(1	pouch)/2,700	
L	drinking	water	for	5-10d.		
Automatic	proportioners:		
Stock	solution:	450	g	(1	pouch)	
of	powder	in	20.25	L	of	water.	
Medicates	2,700	L.		
Set	to	distribute	30	mL	stock	
solution/4	L	of	water.		
Sulfamerazine	(electrolytes,	
sulfamethazine,	sulfathiazole,	
vitamins	 Sulmed	Plus	(Medprodex)	 ```	
	
Sulfavite	(Dominion)	 Sulfavite	(Dominion)	
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Sulfamethazine	
Sodium	Sulfamethazine	Solution	
25%	(Dominion),	Sodium	
Sulfamethazine	Solution	25%	
(P.V.L.),	Sulfa	25%	Solution	(Bimeda-
MTC)	
25	mL/40	kg	b.w.	for	first	day,	
then	reduce	dose	by	1/2	for	
next	3d.	
	
Sodium	Sulfamethazine	Solution	
12.5%	(Dominion)	
2.5	mL/45	kg	b.w.	for	first	day,	
then	reduce	dose	by	1/2	for	
next	3d.	
Sulfamethazine	(sulfathiazole)	
Sulfa	MT	(Jaapharm),	2	Sulfamed	
(Medprodex		
Group	treatment:	Dissolve	567	
g	in	10	L	of	water.	Add	this	
stock	solution	to	350	L	of	
drinking	water	for	the	1st	day.	
For	each	of	the	next	5d,	add	
the	same	quantity	of	stock	
solution	to	500	L	of	drinking	
water.		
Individual	treatment:	Prepare	
either	a	12.5%	OR	a	25%	
solution	by	dissolving	567	g	or	
1134	g,	respectively,	in	water	
to	make	a	total	volume	of	4.5	L.		
As	a	drench:	80	mL	of	12.5%	
solution,	OR	40	mL	of	25%	
solution,	per	50	kg	b.w.	the	first	
day,	and	per	100	kg	b.w.	per	
day	for	the	next	3d.		
	
Sulfa-MT	(Pr)	(Vetoquinol),	Sulfa	2	
Soluble	Powder	(Dominion)	
Dosage	calculations	are	based	
on	a	water	consumption	of	23-
38	L/head/day.		
Herd	medication:	Dissolve	400	
g	(1	pouch)/8	L	water.	Add	this	
to	each	260	L	of	water	on	Day	1	
and	to	each	355	L	of	water	
Days	2-4.		
Automatic	proportioner:	Set	
apparatus	to	deliver	30	mL	
stock	solution/3.78	L	water	(1	
oz/gal	U.S.).	Prepare	stock	
solution	by	dissolving	400	g	(1	
pouch)/2	L	water	for	Day	1	and	
400	g	(1	pouch)/2.8	L	water	
Days	2-4.		
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Powder	21	(P.V.L.)	
Pre-mix	1	package	in	11	L	
water.	Add	to	each	400	L	of	
drinking	water	on	the	first	day,	
and	to	each	500	L	on	the	
second	and	subsequent	days.		
Drench:	Give	60	mL	of	a	12.5%	
solution	OR	30	mL	of	a	25%	
solution	per	34	kg	b.w.	Reduce	
dose	by	1/2	on	the	second,	
third,	and	fourth	days.		
12.5%	solution:	Dissolve	1	
package/4.5	L	water		
25%	solution:	Dissolve	2	
package/4.5	L	water.	
Sulfapyridine	(sulfamethazine,	
sulfathiazole)**	 Neutral	Sulfa	(P.V.L.)	
75	mL/4.5	L	of	water.	Give	
treated	water	as	sole	source	of	
drinking	water	for	3-5d.	
Tetracycline	 Tetracycline	250	(Vetoquinol)	
400	g:	Dissolve	1	g/25	kg	b.w.	
q12h,	given	as	a	drench	using	a	
dose	syringe	or	2	g/4	L	or	400	g	
(1	pouch)/800	L	drinking	water	
for	4-5d.	10	kg:	Dissolve	1	g	
powder/25	kg	b.w.	q12h,	given	
as	a	drench	using	a	dose	
syringe	or	2	g/4	L	or	100	g/200	
L	drinking	water	for	4-5d.	
Automatic	proportioner:	400	g:	
Set	to	distribute	30	mL/4	L	
drinking	water	(1	oz/gal	U.S.).	
Prepare	stock	solution	by	
dissolving	400	g	(1	pouch)/6	L	
water.	This	will	medicate	800	L	
drinking	water.	10	kg:	Set	to	
distribute	30	mL/4	L	drinking	
water	(1	oz/gal	U.S.).	Prepare	
stock	solution	by	dissolving	200	
g/3	L	water.	This	will	medicate	
400	L	drinking	water.	
	
Tetracycline	Hydrochloride	(P.V.L.),	
Tetracycline	Hydrochloride	
(Dominion)	 2	tsp/2.5	L	of	water	or	milk.	
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Onycin	1000	(Pr)	(Vetoquinol),	Tetra	
1000	and	250	(Dominion),	Tetramed	
1000	and	250	(Medprodex)	
1000:	1	g/100	kg	b.w.	q12h,	
given	as	a	drench,	OR	1	g/8	L	of	
water,	OR	25	g	pouch/200	L	of	
drinking	water	for	4-5d.		
Automatic	proportioner:	Set	to	
distribute	30	mL/4	L	drinking	
water	(1	oz/gal).	Prepare	stock	
solution	by	dissolving	50	g	
powder/3	L	water.	This	will	
medicate	400	L	drinking	water.	
250:	1	g/25	kg	b.w.	q12h,	given	
as	a	drench	OR	2	g/4	L	of	
drinking	water,	OR	1x100	g	
pouch/200	L,	OR	1x400	g	
pouch/800	L	of	drinking	water	
for	4-5d.		
Tetracycline	(neomycin	sulfate)	 Neo-Chlor®	(Pr)	(Vetoquinol)	
Swine	and	newborn	piglets:		
100	g,	10	kg	sizes:	Dissolve	4	g	
powder/170	mL	water/45	kg	
b.w.	as	a	drench	or	dissolve	200	
g	(2	pouches)	powder/225	L	
water	for	4-5d.		
400	g	size:	Dissolve	4	g	powder	
in	170	mL	water/45	kg	b.w.	as	a	
drench	or	dissolve	800	g	(2	
pouches)/900	L	water	for	4-5d.	
	
Neo-Tetramed	(Medprodex)	
Swine:	2	g/170	mL	of	water	per	
45	kg	b.w.	as	a	drench	OR	100	
g/225	L	drinking	water	for	4-5	
d.		
Newborn	piglets:	4	g/60	mL	
water	and	give	5	mL/piglet	
q12h	for	4-5d.	
	
Tetra	1000	and	250(Jaapharm)	and	
55	
1000:	225	mg/100	lb	b.w.	q12h	
for	3-4d.																																																	
250:	Swine:	2.5	g	(5/8	tsp)/5	L	
water	or	milk	for	4-5d.	
Newborn	Piglets:	2	g	(1/2	
tsp)/32	mL	water.	Give	5	mL	
q24h	for	3d.																																																																																																							
55:Swine:	11.2	g/5	L	water	or	
milk	for	4-5d.	Newborn	pigs:	8	
g/28	mL	water.	Give	5	mL	q24h	
for	3d.		
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Tiamulin	 Tiamulin	HF	10%	(Bio	Agri	Mix)	
1.65	kg/tonne	feed.	Feed	as	
sole	ration	for	14d.	
	
Denagard™	10%	GF	Premix	(Pr)	
(Elanco	(Novartis))	 1.65	kg/tonne	for	14d.	
Tildipirosin	 Zuprevo	(40	mgéml)	 4	mg/kg	once	
Tilmicosin	
Pulmotil™	Premix	(Pr)	(Elanco	
(Novartis)),	Tilmovet®	Premix	
(Huvepharma	AD)	
1)	2	kg/998	kg	(400	g	
tilmicosin/tonne)	in	complete	
feed.	Feed	for	21d,	beginning	
~7d	before	anticipated	disease	
outbreak.	Feed	continuously	as	
sole	ration.																														2)1	
kg/999	kg	(200	g	
tilmicosin/tonne)	in	complete	
feed.	Feed	for	21d,	beginning	
~7d	before	anticipated	disease	
outbreak.	Feed	continuously	as	
sole	ration.		
	
Pulmotil™	AC	(Pr)	(Elanco	(Novartis))	
Administer	continuously	in	
drinking	water	for	5	
consecutive	days	at	a	
concentration	of	200	mg	
tilmicosin/L	(80	mL	Pulmotil	
AC/100	L	water),	which	is	
equivalent	to	a	daily	dose	of	20	
mg	tilmicosin/kg	b.w.	for	pigs	
that	are	drinking	10%	of	their	
body	weight.		
Trimethoprim	(with	sulfadoxine)	
Trimidox	(Pr)	(Vetoquinol),	Norovet	
TMPS	(Pr)	(Kane	Veterinary	
Supplies),	Dofatrim-ject	(Pr)	(Rafter	
8)	
1	mL/15	kg	(16	mg/kg)	b.w.	
q24h.		
Piglets	<4.5	kg	(10	lb):	0.5	mL	
maximum.	Treat	2-3d	after	
symptoms	have	subsided,	5d	
maximum.		
	
Borgal®	(Pr)	(Merck	Animal	Health)	
3	mL/45	kg	(16	mg/kg)	b.w.	
q24h.		
Piglets	<4.5	kg	b.w.:	0.5	mL	
maximum.		
Tulathromycin	
Draxxin®	25	Injectable	Solution	(Pr)	
(Zoetis),	Draxxin®100	Injectable	
Solution	(Pr)	(Zoetis)	
2.5	mg/kg	(1	mL/10	kg)	b.w.	in	
the	neck.		
Tylosin	
Tylan™	200	Injection	(Pr)	(Elanco	
(Novartis))	
1/2-2	mL/45	kg	(100	lb)	
b.w./day	[2.2-8.8	mg/kg	b.w.	or	
1-4	mg/lb	b.w.].	
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Tylvalosin	(tartrate)	
Aivlosin®	Water	Soluble	Granules	
(Pr)	(Pharmgate	Animal	Health)	
5	mg	tylvalosin/kg	b.w./day.	
Use	continuously	for	5	
consecutive	days.		
